Clinical variables associated with achieving improvement in asthma control with mepolizumab in patients from the REDES study

<bold>Background:</bold> Mepolizumab improves disease control in patients with severe asthma (SA). <bold>Aims:</bold> Assess baseline clinical variables associated with asthma control with mepolizumab in patients with SA. <bold>Methods:</bold> REDES is a retrospective, multicentric study in patients with SA (≥18 years), newly prescribed mepolizumab (physician decision) 100mg subcutaneously with ≥12 months of medical records pre-enrollment. This post hoc analysis assessed baseline clinical variables associated with achieving improvement in asthma control (Asthma Control Test [ACT] score improvement cut-off point: <20/≥20) at Month 12 and 24 post mepolizumab exposure. <bold>Results:</bold> At Month 12, baseline BEC ≥700cells/µL (vs <150cells/µL) and FeNO 25–50ppb (vs <25ppb) were positively associated with ACT score improvement (OR [95% CI]: BEC ≥700cells/µL, 5.82 [1.93, 17.58; p<0.01]; FeNO 25–50ppb, 2.58 [1.05, 6.36; p<0.05]) (Table). At Month 12 and 24, baseline presence of anxiety and/or depression was negatively associated with ACT score improvement (OR [95% CI]: Month 12, 0.54 [0.30, 0.96; p<0.05]; Month 24, 0.18 [0.05, 0.75; p<0.05]). No other baseline clinical variables were significantly associated with ACT score improvement. <bold>Conclusions:</bold> Long-term mepolizumab effectiveness in achieving asthma control may be associated with clinical variables including inflammatory markers and comorbid anxiety/depression. Funding: GSK (213172) <fig><object-id>erj;64/suppl_68/PA5362/F1</object-id><object-id>F1</object-id><object-id>F1</object-id><graphic></graphic></fig>